Aduro Biotech Inc. (NASDAQ:ADRO) was up 3.4% on Thursday . The stock traded as high as $13.74 and last traded at $13.68, with a volume of 118,595 shares. The stock had previously closed at $13.23.

Several brokerages have commented on ADRO. Roth Capital reiterated a “buy” rating and issued a $22.00 price target on shares of Aduro Biotech in a research report on Monday, July 11th. FBR & Co reiterated a “buy” rating on shares of Aduro Biotech in a research report on Monday, June 6th. Canaccord Genuity reiterated a “buy” rating on shares of Aduro Biotech in a research report on Monday, May 16th. Leerink Swann reiterated a “buy” rating and issued a $48.00 price target on shares of Aduro Biotech in a research report on Thursday, May 5th. Finally, Zacks Investment Research cut shares of Aduro Biotech from a “buy” rating to a “hold” rating in a research report on Monday, March 28th. Two analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $24.17.

The stock has a 50 day moving average of $11.94 and a 200-day moving average of $13.98. The company’s market cap is $883.23 million.

Aduro Biotech (NASDAQ:ADRO) last released its quarterly earnings data on Monday, May 2nd. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by $0.20. Analysts expect that Aduro Biotech Inc. will post ($1.24) earnings per share for the current year.

In other Aduro Biotech news, insider Thomas W. Dubensky sold 25,000 shares of the stock in a transaction on Tuesday, July 5th. The stock was sold at an average price of $11.61, for a total transaction of $290,250.00. Following the completion of the transaction, the insider now directly owns 13,939 shares in the company, valued at $161,831.79. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

An institutional investor recently bought a new position in Aduro Biotech stock. ProShare Advisors LLC bought a new stake in Aduro Biotech Inc. (NASDAQ:ADRO) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 51,296 shares of the company’s stock, valued at approximately $1,443,000. ProShare Advisors LLC owned about 0.08% of Aduro Biotech as of its most recent filing with the SEC.

Aduro Biotech, Inc is a clinical-stage immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases. Its technologies are based on live, attenuated, double-deleted Listeria mononcytogenes (LADD) and cyclic dinucleotides (CDNs).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.